Global DNA Repair Drugs Market 2022 - Industry Briefing

June 2022 | 41 pages | ID: G3FCC1CF15CEEN
Gen Consulting Company

Abstracts

DNA repair drugs are used in repairing damaged DNA and for treating cancers. DNA damage can affect normal cell replicative function and impact rates of apoptosis. Alternatively, damage to genetic material can result in impaired cellular function, cell loss, or the transformation of healthy cells to cancers. The global DNA repair drugs market market is projected to rise by USD 45 billion by 2028, according to a new report by Gen Consulting Company. It is anticipated to expand at a CAGR of 19.8 percent during the forecast period.

This industry report offers market estimates of the global market, followed by a detailed analysis of the application, and region. The global market data on DNA repair drugs can be segmented by application: breast cancer, ovarian cancer. Globally, the breast cancer segment made up the largest share of the DNA repair drugs market. DNA repair drugs market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW). North America captured the largest share of the market in 2021.

The global DNA repair drugs market is highly competitive. The DNA repair drugs market is dominated by key players, which are Abbott Laboratories Inc., AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., The Bristol-Myers Squibb Company (BMS).

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

• Get a detailed picture of the Global DNA Repair Drugs Market
• Identify segments/areas to invest in over the forecast period in the Global DNA Repair Drugs Market
• Understand the competitive environment, the market’s leading players
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. SUMMARY

PART 2. INTRODUCTION

Study period
Geographical scope
Market segmentation

PART 3. DNA REPAIR DRUGS MARKET OVERVIEW

PART 4. MARKET BREAKDOWN BY APPLICATION

Breast cancer
Ovarian cancer

PART 5. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 6. KEY COMPANIES

Abbott Laboratories Inc.
AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Eli Lilly and Company
Gilead Sciences, Inc.
GlaxoSmithKline plc (GSK)
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
The Bristol-Myers Squibb Company (BMS)

PART 7. METHODOLOGY